Sonoma Pharmaceuticals (SNOA) Liabilities and Shareholders Equity (2011 - 2025)

Sonoma Pharmaceuticals' Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $13.6 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity changed 0.33% year-over-year to $13.6 million; the TTM figure through Dec 2025 stood at $55.8 million (changed 0.0% YoY), while the FY2025 annual figure was $13.7 million, down 7.1% from the prior year.
• Liabilities and Shareholders Equity was $13.6 million for Q4 2025 at Sonoma Pharmaceuticals, down from $13.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $19.8 million in Q3 2021 to a low of $13.6 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $15.3 million across 5 years, with a median of $14.6 million in 2023.
• Biggest YoY gain for Liabilities and Shareholders Equity was 25.74% in 2022; the steepest drop was 28.01% in 2022.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $19.3 million in 2021, then retreated by 28.01% to $13.9 million in 2022, then grew by 4.95% to $14.6 million in 2023, then slipped by 6.5% to $13.7 million in 2024, then decreased by 0.33% to $13.6 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $13.6 million (Q4 2025), $13.9 million (Q3 2025), and $14.6 million (Q2 2025), per Business Quant data.